Abstract
Depression is a severe neuropsychiatric disorder affecting approximately 10% of the world population. Despite this, the molecular mechanisms underlying the disorder are still not understood. Novel technologies such as proteomic-based platforms are beginning to offer new insights into this devastating illness, beyond those provided by the standard targeted methodologies. Here, we will show the potential of proteome analyses as a tool to elucidate the pathophysiological mechanisms of depression as well as the discovery of potential diagnostic, therapeutic and disease course biomarkers.
MeSH terms
-
Animals
-
Antidepressive Agents / pharmacology
-
Biomarkers
-
Citalopram / pharmacology
-
Depressive Disorder* / drug therapy
-
Depressive Disorder* / genetics
-
Depressive Disorder* / metabolism
-
Depressive Disorder* / physiopathology
-
Disease Models, Animal
-
Drug Resistance
-
Humans
-
Mice
-
Nucleus Accumbens / drug effects
-
Nucleus Accumbens / metabolism
-
Nucleus Accumbens / pathology
-
Proteome / analysis
-
Proteome / genetics
-
Proteome / physiology
-
Proteomics / methods*
-
Selective Serotonin Reuptake Inhibitors / pharmacology
Substances
-
Antidepressive Agents
-
Biomarkers
-
Proteome
-
Serotonin Uptake Inhibitors
-
Citalopram